{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018497","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.652486+00:00","generated_at":"2026-06-02T06:26:49.332045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Azitra Q1 2024 net loss $2.9M; cash $3.0M; ATR-12/ATR-04 clinical updates","bullets":["Q1 2024 net loss $2.9M vs $2.5M YoY; R&D and G&A each $1.5M vs $0.8M prior year.","Cash and cash equivalents $3.0M as of 3/31/2024; raised $5.0M in Feb 2024 follow-on offering.","ATR-12 Phase 1b trial activated sites, initial patients identified; safety data expected late 2024.","ATR-04 pre-IND meeting completed; IND submission planned mid-2024 for Phase 1b in EGFRi rash.","Bayer joint development agreement progresses; licensing agreement with upfront payment under discussion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018497","json":"https://secwatch.observer/filing/0001493152-24-018497.json","markdown":"https://secwatch.observer/filing/0001493152-24-018497.md","text":"https://secwatch.observer/filing/0001493152-24-018497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/0001493152-24-018497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:26:49.332045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7fd3eb0130a1e34729d60312a0711c89a385dd3","claim":"Azitra, Inc. reported the quarter ended March 31, 2024 results: revenue $0, net income $2.9 million.","evidence_excerpt":"Financial Results for the Year Ended December 31, 2023 ● Service Revenue – Related Party : The Company generated $0 service revenue during the quarter ended March 31, 2024, compared to $113,300 for the comparable period in 2023. ● Research and Development (R&D) expenses : R&D expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● General and Administrative (G&A) expenses : G&A expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● Net Loss was $2.9 million for the quarter ended March 31, 2024, compared to $2.5 million for the comparable period in 2023. ● Cash and cash equivalents : As of March 31, 2024, the Company had cash and cash equivalents of $3.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224018497/0001493152-24-018497-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$0"},{"label":"Net income","value":"$2.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}